18070217|t|In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease.
18070217|a|WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Deficit in central cholinergic neurotransmission is a consistent change associated with Alzheimer's disease (AD). * Donepezil hydrochloride exhibits selective inhibition of acetylcholinesterase (AChE) and is widely used for the treatment of AD. * The biodistribution of donepezil in the brain after administration is not precisely understood in vivo. * There is no method to measure the amount of binding of orally administered donepezil to AChE. WHAT THIS STUDY ADDS: * This study clearly visualizes the distribution of donepezil in human brain using [(11)C]-donepezil and positron emission tomography. * This study demonstrates prominent reduction of the donepezil binding site in the AD brain. * This study provides methodology to measure the AChE binding occupancy of orally administered donepezil and provides a new surrogate marker for evaluation and prediction of response to donepezil treatment. AIMS: The aims of this study were to visualize in vivo binding of donepezil to acetylcholinesterase (AChE) in the brain and to establish a method for measuring the amount of binding of orally administered donepezil. METHODS: [5-(11)C-methoxy]-donepezil ([(11)C]-donepezil) was radiolabelled as a positron emission tomography (PET) tracer. The biodistribution of [(11)C]-donepezil was measured by PET in 10 AD patients and six elderly normal subjects. Two AD patients underwent additional PET measurements after oral administration of donepezil for 6 months. RESULTS: [(11)C]-donepezil-PET images demonstrated high densities of tracer distribution in AChE-rich brain regions such as the striatum, thalamus, and cerebellum. Compared with elderly normal subjects, patients with mild AD exhibited about 18-20% reduction of donepezil binding in the neocortex and hippocampus, while patients with moderate AD exhibited about 24-30% reduction of donepezil binding throughout the brain. Orally administered donepezil (5 mg day(-1)) induced 61.6-63.3% reduction of donepezil binding in AD brains. The distribution volume of [(11)C]-donepezil in the hippocampus was significantly correlated with MMSE scores in AD patients. CONCLUSIONS: [(11)C]-donepezil-PET enables quantitative measurement of donepezil binding in the brain. AD patients exhibited reduction of donepezil binding in the brain, even in the early stage of disease. Longitudinal evaluation by this technique enables determination of AChE binding occupancy of orally administered donepezil.
18070217	25	34	donepezil	Chemical	MESH:D000077265
18070217	59	67	patients	Species	9606
18070217	73	92	Alzheimer's disease	Disease	MESH:D000544
18070217	226	245	Alzheimer's disease	Disease	MESH:D000544
18070217	247	249	AD	Disease	MESH:D000544
18070217	254	277	Donepezil hydrochloride	Chemical	MESH:D000077265
18070217	311	331	acetylcholinesterase	Gene	43
18070217	333	337	AChE	Gene	43
18070217	379	381	AD	Disease	MESH:D000544
18070217	408	417	donepezil	Chemical	MESH:D000077265
18070217	566	575	donepezil	Chemical	MESH:D000077265
18070217	579	584	AChE.	Gene	43
18070217	659	668	donepezil	Chemical	MESH:D000077265
18070217	672	677	human	Species	9606
18070217	690	707	[(11)C]-donepezil	Chemical	-
18070217	795	804	donepezil	Chemical	MESH:D000077265
18070217	825	827	AD	Disease	MESH:D000544
18070217	884	888	AChE	Gene	43
18070217	930	939	donepezil	Chemical	MESH:D000077265
18070217	1021	1030	donepezil	Chemical	MESH:D000077265
18070217	1108	1117	donepezil	Chemical	MESH:D000077265
18070217	1121	1141	acetylcholinesterase	Gene	43
18070217	1143	1147	AChE	Gene	43
18070217	1247	1256	donepezil	Chemical	MESH:D000077265
18070217	1267	1294	[5-(11)C-methoxy]-donepezil	Chemical	MESH:C473648
18070217	1296	1313	[(11)C]-donepezil	Chemical	-
18070217	1404	1421	[(11)C]-donepezil	Chemical	-
18070217	1448	1450	AD	Disease	MESH:D000544
18070217	1451	1459	patients	Species	9606
18070217	1497	1499	AD	Disease	MESH:D000544
18070217	1500	1508	patients	Species	9606
18070217	1576	1585	donepezil	Chemical	MESH:D000077265
18070217	1609	1626	[(11)C]-donepezil	Chemical	-
18070217	1692	1696	AChE	Gene	43
18070217	1803	1811	patients	Species	9606
18070217	1822	1824	AD	Disease	MESH:D000544
18070217	1861	1870	donepezil	Chemical	MESH:D000077265
18070217	1919	1927	patients	Species	9606
18070217	1942	1944	AD	Disease	MESH:D000544
18070217	1981	1990	donepezil	Chemical	MESH:D000077265
18070217	2041	2050	donepezil	Chemical	MESH:D000077265
18070217	2098	2107	donepezil	Chemical	MESH:D000077265
18070217	2119	2121	AD	Disease	MESH:D000544
18070217	2157	2174	[(11)C]-donepezil	Chemical	-
18070217	2243	2245	AD	Disease	MESH:D000544
18070217	2246	2254	patients	Species	9606
18070217	2269	2286	[(11)C]-donepezil	Chemical	-
18070217	2327	2336	donepezil	Chemical	MESH:D000077265
18070217	2359	2361	AD	Disease	MESH:D000544
18070217	2362	2370	patients	Species	9606
18070217	2394	2403	donepezil	Chemical	MESH:D000077265
18070217	2529	2533	AChE	Gene	43
18070217	2575	2584	donepezil	Chemical	MESH:D000077265
18070217	Negative_Correlation	MESH:D000077265	43
18070217	Negative_Correlation	MESH:D000077265	MESH:D000544

